Cantwell B M, Harris A L, Bozzino J M
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S29. doi: 10.1007/BF00647447.
Two studies were carried out (A and B) in order to assess the effectiveness of ifosfamide administered with mesna (IFO/M) in the treatment of small cell lung cancer. The first study (A) was a cross-over study; the second (B) was a randomized trial, and in B IFO/M was evaluated earlier in the course of the disease. IFO/M given be infusion is effective as second-line therapy and can be administered with other cytotoxics at the doses reported here earlier in the course of the disease. The complete remission rates were high.
为评估异环磷酰胺联合美司钠（IFO/M）治疗小细胞肺癌的有效性，开展了两项研究（研究A和研究B）。第一项研究（A）为交叉研究；第二项研究（B）为随机试验，且在研究B中，IFO/M在疾病进程中更早阶段进行评估。静脉输注给予的IFO/M作为二线治疗有效，且在疾病进程更早阶段可按此处报告的剂量与其他细胞毒性药物联合使用。完全缓解率较高。
